The Arbiser lab has made major strides in melanoma in 2015. Honokiol, a small natural product from the Magnolia plant, was found to cause mitochondrial normalization by the Arbiser lab and other labs. Most melanomas contain Braf, and abnormal mitochondria are required for Braf to transform melanoma. The Arbiser lab has developed and patented new derivatives of honokiol. These derivatives normalize the mitochondria in aggressive melanoma cells and inhibit the growth of melanoma cells which are resistant to vemurafenib, the major drug used for melanoma. This paper has been submitted to Oncotarget. In addition, Dr Arbiser has collaborated with Dr Jing Chen to find
Read about recent studies by Dr. Jack Arbiser
Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo Feburary 9th, 2016
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling
PHIPing out: a genetic basis for tumor ulceration
Clinical Cancer Research September 14, 2008
Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78
Please make your donation today to continue this much needed research
Post our link on your own Facebook page by clicking on the icon below.
HELP SPREAD THE WORD!!!